{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:59:03Z","timestamp":1793228343362,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T00:00:00Z","timestamp":1698883200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004337","name":"F Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.lungcan.2023.107418","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T18:55:45Z","timestamp":1698778545000},"page":"107418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"special_numbering":"C","title":["Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide"],"prefix":"10.1016","volume":"186","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4852-3914","authenticated-orcid":false,"given":"Stephen V.","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony S.K.","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barzin Y.","family":"Nabet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"De Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy","family":"Losonczy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichi","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafal","family":"Dziadziuszko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Krzakowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexey","family":"Smolin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian J.","family":"Hochmair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina C.","family":"Garassino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl M.","family":"Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John V.","family":"Heymach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren A.","family":"Byers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivuonthanh","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Shames","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Reck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2023.107418_b0005","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.lungcan.2023.107418_b0010","unstructured":"J. Ferlay, M. Ervik, F. Lam, et al, Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: https:\/\/gco.iarc.fr\/today, 2020 (accessed October 13, 2021)."},{"key":"10.1016\/j.lungcan.2023.107418_b0015","unstructured":"Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2018, National Cancer Institute. Bethesda, MD, Available from: https:\/\/seer.cancer.gov\/csr\/1975_2018\/, 2020 (accessed March 16, 2023)."},{"key":"10.1016\/j.lungcan.2023.107418_b0020","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2023.107418_b0025","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1080\/17476348.2021.1964362","article-title":"Immune checkpoint inhibitors: a new landscape for extensive stage small cell lung cancer treatment","volume":"15","author":"Bianco","year":"2021","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.lungcan.2023.107418_b0030","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2023.107418_b0035","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107418_b0040","unstructured":"TECENTRIQ (atezolizumab) [package insert]. South San Francisco, CA: Genentech, Inc.; 2023."},{"key":"10.1016\/j.lungcan.2023.107418_b0045","unstructured":"TECENTRIQ (atezolizumab) [summary of product characteristics]. Grenzach-Wyhlen, Germany: Roche GmbH; 2023."},{"key":"10.1016\/j.lungcan.2023.107418_b0050","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2023.107418_b0055","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2023.107418_b0060","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study","volume":"38","author":"Rudin","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107418_b0065","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","article-title":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","volume":"19","author":"Rudin","year":"2019","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.lungcan.2023.107418_b0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.lungcan.2023.107418_b0075","doi-asserted-by":"crossref","first-page":"741","DOI":"10.3389\/fonc.2020.00741","article-title":"Targeted therapies and biomarkers in small cell lung cancer","volume":"10","author":"Taniguchi","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2023.107418_b0080","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.hoc.2003.12.011","article-title":"Prognostic factors of small cell lung cancer","volume":"18","author":"Buccheri","year":"2004","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.lungcan.2023.107418_b0085","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0169-5002(02)00508-1","article-title":"The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up","volume":"39","author":"Bremnes","year":"2003","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2023.107418_b0090","doi-asserted-by":"crossref","first-page":"6429","DOI":"10.2147\/CMAR.S326189","article-title":"Prognostic value of Ki-67 expression in advanced lung squamous cell carcinoma patients treated with chemotherapy","volume":"13","author":"Wang","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.lungcan.2023.107418_b0095","first-page":"1732","article-title":"The importance of Ki-67 proliferation index in small cell lung cancer","volume":"56","author":"Beyhan Sagmen","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.lungcan.2023.107418_b0100","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2023.107418_b0105","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ccell.2019.01.011","article-title":"Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer","volume":"35","author":"Hellmann","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lungcan.2023.107418_b0110","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","article-title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","volume":"39","author":"Gay","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lungcan.2023.107418_b0115","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","article-title":"xCell: digitally portraying the tissue cellular heterogeneity landscape","volume":"18","author":"Aran","year":"2017","journal-title":"Genome Biol."},{"key":"10.1016\/j.lungcan.2023.107418_b0120","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S0092-8674(00)80702-3","article-title":"A novel transcription factor, T-bet, directs Th1 lineage commitment","volume":"100","author":"Szabo","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.lungcan.2023.107418_b0125","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1073\/pnas.0538056100","article-title":"Single-cell perforin and granzyme expression reveals the anatomical localization of effector CD8+ T cells in influenza virus-infected mice","volume":"100","author":"Johnson","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.lungcan.2023.107418_b0130","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1126\/science.1090148","article-title":"Control of effector CD8+ T cell function by the transcription factor Eomesodermin","volume":"302","author":"Pearce","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.lungcan.2023.107418_b0135","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cell.2014.12.033","article-title":"Molecular and genetic properties of tumors associated with local immune cytolytic activity","volume":"160","author":"Rooney","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.lungcan.2023.107418_b0140","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","article-title":"Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab","volume":"24","author":"Gandara","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.lungcan.2023.107418_b0145","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/bioinformatics\/btq057","article-title":"Fast and SNP-tolerant detection of complex variants and splicing in short reads","volume":"26","author":"Wu","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.lungcan.2023.107418_b0150","doi-asserted-by":"crossref","first-page":"e1003118","DOI":"10.1371\/journal.pcbi.1003118","article-title":"Software for computing and annotating genomic ranges","volume":"9","author":"Lawrence","year":"2013","journal-title":"PLoS Comput. Biol."},{"key":"10.1016\/j.lungcan.2023.107418_b0155","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2023.107418_b0160","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1093\/nar\/gkv007","article-title":"limma powers differential expression analyses for RNA-sequencing and microarray studies","volume":"43","author":"Ritchie","year":"2015","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.lungcan.2023.107418_b0165","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.annonc.2021.05.799","article-title":"VP5-2021: IMpower133: gene expression (GE) analysis in long-term survivors (LTS) with ES-SCLC treated with first-line carboplatin and etoposide (CE) \u00b1 atezolizumab (atezo)","volume":"32","author":"Liu","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2023.107418_b0170","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/0169-5002(95)00594-3","article-title":"Long-term survival in small cell lung cancer: the case for a standard definition. Medical Research Council Lung Cancer Working Party","volume":"15","author":"Stephens","year":"1996","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2023.107418_b0175","doi-asserted-by":"crossref","first-page":"S724","DOI":"10.1016\/j.jtho.2016.11.957","article-title":"P1.07-045 Characteristics of exceptional long term survivors in extensive stage small cell lung cancer,","volume":"12","author":"Maneenil","year":"2017","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2023.107418_b0180","doi-asserted-by":"crossref","first-page":"S1168","DOI":"10.1016\/j.annonc.2021.08.242","article-title":"1658P Clinical characteristics of long-term survivors (LTS) in small cell lung cancer (SCLC) patients (p) with extended disease (ED)","volume":"32","author":"Plaja","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2023.107418_b0185","doi-asserted-by":"crossref","first-page":"S1212","DOI":"10.1016\/j.annonc.2020.08.2328","article-title":"LBA86 Durvalumab (D) \u00b1 tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN","volume":"31","author":"Goldman","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2023.107418_b0190","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jtho.2019.10.004","article-title":"Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 randomized cohort","volume":"15","author":"Ready","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2023.107418_b0195","first-page":"1875","article-title":"A high number of tumor-infiltrating lymphocytes are associated with a small tumor size, low tumor stage, and a favorable prognosis in operated small cell lung carcinoma","volume":"6","author":"Eerola","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2023.107418_b0200","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.jtho.2019.01.019","article-title":"Surgical resection of SCLC: prognostic factors and the tumor microenvironment","volume":"14","author":"Zhao","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2023.107418_b0205","doi-asserted-by":"crossref","first-page":"e242","DOI":"10.1016\/j.jtho.2019.06.029","article-title":"Immune cell infiltration is a strong prognostic indicator in surgical resection of SCLC","volume":"14","author":"Zhou","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2023.107418_b0210","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/j.jtho.2019.03.028","article-title":"Immune cell infiltration may be a key determinant of long-term survival in small cell lung cancer","volume":"14","author":"Muppa","year":"2019","journal-title":"J. Thorac. Oncol."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022300956X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022300956X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:06:17Z","timestamp":1759237577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016950022300956X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":42,"alternative-id":["S016950022300956X"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107418","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107418","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107418"}}